

## INFORMATION STATEMENT

Lund, June 7th, 2006

# TFS Trial Form Support International awarded global decentralised study management contract

TFS Trial Form Support International was in April 2006 awarded a global Master Service Agreement for its capability in allocating Study Managers to international clinical trials from a number of key-countries in Europe. Out of eight vendors TFS was finally selected to support a major multi-international UK-based pharmaceutical company with Study Managers appointed through a new decentralised model. The TFS affiliates that were selected to supply Study Managers to international clinical trials in accordance to the Master Service Agreement were; Sweden, Denmark, Norway, Finland, the UK, Spain, Italy and Portugal.

The decentralised Study Manager model is based on the Study Managers' competence, therapeutic expertise and experience from international clinical trials. This model has many advantages compared to the traditional way of allocating Study Managers at the main R&D sites. It furthermore increases the flexibility and availability of Study Managers.

"The concept is very much a new approach from the large pharmaceutical companies to secure their resourcing need of these highly experienced and competent people. As a CRO we are of course welcoming this new way of thinking about resourcing possibilities", says Chief Executive Officer, Mr. Daniel Spasic.

The international studies will be initiated from the customers' R&D sites but instead of consolidating all the Study Manager positions to the main R&D sites these will be spread across Europe to manage the international trials. The remaining functions of the Study Team will mainly be resourced by the client's own operational personnel. "This client has put the Study Manager's competence, experience and personality in front of geographical placement, which is the way CROs have been working for decades" continues Mr. Spasic.

This innovative approach taken by a leading international pharmaceutical company will secure their key-competences in the Study Team and also the performance of the clinical trial. "I hope more pharmaceutical and biotech companies will follow this model, even though it's based on a strong pipeline and a critical mass of studies in order to be optimised in the best possible way", ends Mr. Spasic.

The value of the Master Service Agreement is significant but confidential.

